Skip to main content
Jafron Biomedical Co.,Ltd. logo

Jafron Biomedical Co.,Ltd. — Investor Relations & Filings

Ticker · 300529 ISIN · CNE100002995 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,842 across all filing types
Latest filing 2024-02-29 Governance Information
Country CN China
Listing Shenzhen Stock Exchange 300529

About Jafron Biomedical Co.,Ltd.

https://www.jafron.com

Jafron Biomedical Co.,Ltd. specializes in the research, development, and manufacturing of biomaterials and equipment for blood purification. The company is a primary provider of hemoperfusion technology, focusing on the production of adsorbent cartridges designed to remove specific toxins and inflammatory mediators from the bloodstream. Its core product portfolio includes the HA series of hemoperfusion cartridges, which are applied in clinical settings for end-stage renal disease, acute poisoning, critical care, and liver failure. Beyond consumables, the company develops blood purification machines and integrated treatment systems. These solutions target clinical applications in nephrology, intensive care, and hepatology. By leveraging advanced resin adsorption technology, the company provides specialized extracorporeal blood treatment options aimed at improving patient outcomes in complex medical conditions.

Recent filings

Filing Released Lang Actions
外汇套期保值业务管理制度（2024年2月）
Governance Information Classification · 95% confidence The document is titled as a management system for foreign exchange hedging business of the company, detailing internal policies, operational principles, approval authorities, risk management, and disclosure requirements. It is a regulatory or internal governance document rather than a financial report, earnings release, or announcement. It does not contain financial statements or results, nor is it a brief announcement or presentation. It is a detailed governance and procedural document related to the company's internal controls and compliance with laws and regulations. Therefore, it fits best under Governance Information (CGR). The document length is 3638 characters, which is not very short, and it is not an announcement of a report publication or certification. Hence, the classification is CGR with high confidence.
2024-02-29 Chinese
关于开展外汇套期保值业务的可行性分析报告
Regulatory Filings Classification · 95% confidence The document is titled as a feasibility analysis report regarding the company's plan to conduct foreign exchange hedging business. It discusses the purpose, basic conditions, risk analysis, risk control measures, accounting treatment, and concludes on the feasibility of the hedging business. There is no indication that this is an announcement of a report publication, nor is it a certification or a brief summary. The content is a detailed internal analysis report related to financial risk management and hedging activities, which does not fit into categories like Annual Report, Interim Report, or Earnings Release. It is not a regulatory filing or a general announcement but a specific business feasibility report. Given the filing definitions, this document best fits under Regulatory Filings (RNS) as it is a regulatory announcement/report about a specific financial risk management activity that does not fall under other specific categories.
2024-02-29 Chinese
关于开展外汇套期保值业务的公告
Regulatory Filings Classification · 95% confidence The document is an announcement by a company regarding its decision to engage in foreign exchange hedging activities. It details the purpose, amount, transaction types, risk analysis, risk control measures, accounting treatment, and approvals by the board and supervisory committee. The document is a formal disclosure of a corporate decision and risk management strategy related to financial derivatives and hedging, not a financial report or earnings release. It is not a report publication announcement since it contains substantive information about the transaction and approvals. It is not a management report or earnings release as it does not contain financial results or performance data. It is not a capital/financing update in the sense of fundraising or capital structure changes. The document fits best as a Regulatory Filing (RNS) because it is a regulatory disclosure about a significant business activity and risk management measure that does not fall into other specific categories.
2024-02-29 Chinese
第五届董事会独立董事2024年第二次专门会议决议
Board/Management Information Classification · 95% confidence The document is a resolution from the independent directors of the company's fifth board, specifically the second special meeting in 2024. It discusses the approval of a proposal related to foreign exchange hedging business and confirms compliance with relevant laws and company regulations. There is no financial data, no mention of annual or quarterly reports, no earnings data, no shareholder voting results, and no mention of management changes. The document is a board/management related announcement about a specific board meeting decision. Therefore, it fits best under Board/Management Information (MANG). The document length is short and it is not an announcement of a report publication, so it is not RPA or RNS.
2024-02-29 Chinese
第五届董事会第十七次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at the 17th meeting of the 5th Board of Directors of the company. It details the meeting attendance, the approval of proposals related to foreign exchange hedging business, and the adoption of a management system for such business. It includes voting results and references to related documents disclosed on a regulatory website. The content focuses on board decisions and governance matters rather than financial results, audit opinions, or shareholder voting outcomes. The document length is short (1283 characters), and it is clearly a board meeting resolution announcement. Therefore, it fits best under 'Board/Management Information' (MANG).
2024-02-29 Chinese
中航证券有限公司关于健帆生物科技集团股份有限公司开展外汇套期保值业务的核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed opinion and verification report from a sponsoring institution (中航证券有限公司) regarding the company's (健帆生物科技集团股份有限公司) plan to conduct foreign exchange hedging business. It includes descriptions of the business purpose, transaction amounts, risk analysis, risk control measures, accounting treatment, and approvals from independent directors, the supervisory board, and the sponsor. The document is not a financial report, earnings release, or regulatory filing but rather a formal verification and opinion report related to a specific financial activity (foreign exchange hedging). It does not fit categories like Annual Report, Interim Report, or Earnings Release. It is a standalone audit or verification type report related to internal controls and compliance for a specific financial transaction. Therefore, it best fits the category of Audit Report / Information (AR). The document length is 3155 characters, which is sufficient for a detailed report but not a full annual or interim report. Hence, the classification is AR with high confidence. Q1 2024
2024-02-29 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.